Research Article
Altered AKT1 and MAPK1 Gene Expression on Peripheral Blood Mononuclear Cells and Correlation with T-Helper-Transcription Factors in Systemic Lupus Erythematosus Patients
Table 1
Clinical parameters and treatments of SLE patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aSystemic Lupus Erythematosus Disease Activity index (SLEDAI). bW: woman; M: man. cAge (years). dL: Lymphocytes/mL. eComplement C3 and C4 (low <90 and/or <10, mg/dL). fND: no determined. gSLE patients presented anti-double stranded DNA auto antibodies (31%, three women and one man). hRD: renal disease, (23% of SLE patients). iCRP: C-reactive protein (mg/dL). jN: Neutrophils/microliter. kDd: Disease duration, at the time of the study, in years (y). lHCQ: hydroxychloroquine; PN: prednisone; MTX: methotrexate; AZA: azathioprine; MMF: mycophenolate mofetil; NT: no treatment. mMedian (25th to 75th percentiles). nn = 12. |